Satellos Bioscience Inc. saw a notable increase in its stock price, gaining 3.34% in yesterday's trading session.
In yesterday's trading session, Satellos Bioscience Inc. (MSCL.TO) closed at CA$11.13. This positive movement reflects growing investor interest, likely driven by recent developments in the company's clinical pipeline.
Investor takeaway: Investors may view Satellos as a company on the rise, particularly with its promising drug candidates receiving regulatory attention.
Advertisement
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$221.08M
52W high
$18.98
52W low
$7.56
1W change
-13.81%
Beta
1.15
Analyst Price Targets
Based on analyst covering MSCL · as of Sep 28, 2026
Wall Street analysts forecast MSCL stock price to rise 67.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.47
+67.7% Upside
Previously C$17.67 on Sep 17, 2026
Current Price
C$10.42
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
57.0%
Annualized
90-Day Vol
72.1%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$8.72
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.82 | C$8.06 – C$11.95 |
| 60 trading days | C$9.25 | C$7.00 – C$12.22 |
| 90 trading days | C$8.72 | C$6.20 – C$12.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Satellos Bioscience Inc. Gains 3.34% in One Day
The stock's market capitalization now stands at CA$236.14 million, highlighting its growth potential in the biotech sector.
Bull case
The FDA's clearance of the IND for forazapadin, aimed at treating FSHD, is a significant milestone for Satellos. This approval could boost investor confidence and spark further interest in the stock as clinical trials progress.
Bear case
Despite the positive movement, Satellos is still a small-cap company with inherent risks. Its lack of profitability and dependence on future clinical trial outcomes may deter some conservative investors.
Advertisement
Recent Developments Fuel Investor Interest
Satellos gained momentum after the FDA cleared its Investigational New Drug application for forazapadin, which targets facioscapulohumeral muscular dystrophy (FSHD). This approval is a crucial step for the company, potentially paving the way for successful clinical trials and future revenue streams. Investors are likely optimistic about the upcoming Phase 2 study scheduled for Q4 2026.
Market Response and Future Outlook
The stock's increase in value reflects a broader market response to the company's advancements in drug development. With a market cap of CA$236.14 million, Satellos is positioned within the competitive biotech landscape. However, investors should remain cautious, as the company's profitability remains unproven, and its success hinges on the outcomes of ongoing clinical trials. For more insights on Satellos, visit our stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
